NP38619 Compounded Aseptic Medicines

Descriptions

This Framework Agreement is for the supply of unlicensed, aseptically compounded, ready to use medicines in syringe and infusion bags to NHS Scotland. The Goods have been separated into four (4) categories, each of which is identified as a “Lot”. Lot 1 - Atezolizumab, Cetuximab, Doxorubicin, Epirubicin, Infliximab (Inflectra®), (Remicade®), (Remsima®) Nivolumab, Pembrolizumab & Pertuzumab Lot 2 - Cyclophosphamide, Fluorouracil, Irinotecan, Methotrexate & Rituximab (Mabthera®), (Rixathon®), (Truxima®) Lot 3 - Bortezomib, Carboplatin, Cisplatin, Docetaxel, Gemcitabine, Oxaliplatin, Vincristine & Trastuzumab (Herceptin®), (Herzuma®) Lot 4 - The molecules included in this Lot are, Bevacizumab, Cytarabine, Infliximab (Zessly®), Insulin, Methotrexate, Natalizumab, Nivolumab, Paclitaxel, Pemetrexed, Tocilizumab, Trastuzumab (Kanjinti®), (Ontruzant®), Trastuzumab Subcutaneous & Vedolizumab The Framework Participant was required to supply Goods to designated delivery points throughout Scotland for use by Participating Authorities.